|Summary sheet: 2C-C|
|Routes of Administration|
4-Chloro-2,5-dimethoxyphenethylamine (commonly known as 2C-C) is a lesser-known psychedelic substance of the phenethylamine class that produces psychedelic effects when administered. It is a member of the 2C-x family of psychedelic phenethylamines, all of which were derived from the systematic modification of the mescaline molecule.
2C-C was first synthesized by Alice C. Cheng and Neal Castagnoli Jr. in 1983 as an intermediate in a study evaluating the neurotoxicity of 6-hydroxydopamine analogs. Its activity in humans was later investigated and documented by Alexander Shulgin in his book PiHKAL ("Phenethylamines I Have Known and Loved").
Many users report that the effects of 2C-C are gentler, more relaxed, and sedating than other closely related psychedelic phenethylamines such as 2C-B, 2C-I, and 2C-E. It is considered to be one of the least potent members of the 2C-x family, with muted visual effects and a relatively unaltered headspace.
Very little data exists about the pharmacological properties, metabolism, and toxicity of 2C-C, and its history of human use is limited. Today, it is used for recreational and therapeutic purposes. It is rarely sold on the streets and distributed online as a grey area research chemical.
- 1 Chemistry
- 2 Pharmacology
- 3 Subjective effects
- 4 Toxicity and harm potential
- 5 Legal status
- 6 See also
- 7 External links
- 8 References
2C-C or 2,5-dimethoxy-4-chlorophenethylamine is a substituted phenethylamine featuring a phenyl ring bound to an amino (NH2) group through an ethyl chain. 2C-C contains methoxy functional groups CH3O- attached to carbons R2 and R5 as well as a chlorine atom attached to carbon R4 of the phenyl ring. 2C-C belongs to the 2C family of phenethylamines which contain methoxy groups on the 2 and 5 positions of the benzene ring.
2C-C's psychedelic effects are believed to come from its efficacy at the 5-HT2A receptor as a partial agonist. However, the role of these interactions and how they result in the psychedelic experience is the subject of ongoing scientific investigation.
The effects listed below are based upon the subjective effects index and personal experiences of PsychonautWiki contributors. The listed effects should be taken with a grain of salt and will rarely (if ever) occur all at once, but heavier doses will increase the chances and are more likely to induce a full range of effects. Likewise, adverse effects become much more likely on higher doses and may include serious injury or death.
- Stimulation & Sedation - In terms of its effects on the physical energy levels of the user, the 2C-C experience typically begins with mild stimulation, but usually becomes somewhat sedating as the experience progresses and lacks the distinctive energetic feeling associated with most phenethylamines. This is described in PiHKAL as "an intense form of relaxation."
- Spontaneous physical sensations - The "body high" of 2C-C can be described as a pleasurable, warm, soft, all-encompassing and mild tingling sensation. This maintains a consistent presence that steadily rises with the onset and hits its limit once the peak has been reached.
- Tactile enhancement
- Bodily control enhancement - Whilst at lower doses one may find that their bodily control is enhanced, at higher dosages this becomes suppressed.
- Temperature regulation suppression
- Increased heart rate
- Nausea - Although nausea remains present, in comparison to other phenethylamines such as 2C-E, 2C-I or 2C-B, this remains relatively mild and tends to dissipate quickly. It is considered by some to be one of the most physically understated psychedelics known.
- Pupil dilation
- Teeth grinding - This component can be considered to be less intense when compared with that of MDMA.
- Drifting (melting, flowing, breathing and morphing) - In comparison to other psychedelics, this effect can be described as highly detailed, slow and smooth in motion, static in appearance and realistic in style.
- Colour shifting
2C-C can produce a full range of hallucinatory states in a fashion that is more consistent and reproducible than that of many other commonly used psychedelics. However, the dose required to reach this state is significantly higher than many related 2C-x phenethylamines. These effects include:
- Internal hallucinations (autonomous entities; settings, sceneries, and landscapes; alterations in perspective and scenarios and plots) - 2C-C is capable of producing high levels of hallucinogenic imagery, although typically only at very heavy doses. When this effect does occur, it commonly contains hallucinations with scenarios, settings, concepts and autonomous entity contact. They are more common within dark environments and can be described as internal in their manifestation, lucid in believability, interactive in style and almost exclusively of a personal, religious, spiritual, science-fiction, fantasy, surreal, nonsensical or transcendental nature in theme.
- External hallucinations (autonomous entities; settings, sceneries, and landscapes; alterations in perspective and scenarios and plots) - 2C-C is capable of external hallucinations embedded within visual geometry. This particular effect commonly contains hallucinations with scenarios, settings, concepts and autonomous entity contact. They can be described as external in their manifestation, lucid in believability, interactive in style and almost exclusively of a personal, religious, spiritual, science-fiction, fantasy, surreal, nonsensical or transcendental nature in their overall theme.
The head space of 2C-C is described by many as one which is both insightful and relatively normal in its thought processes even at moderate to high dosages.
- Empathy, affection, and sociability enhancement - This component is consistently manifested only in the context of social settings in which one is within the company of others. These feelings of sociability, love and empathy are not as pronounced than those found on substances such as MDMA or 2C-B. They primarily manifest during the stimulating onset of the experience and dissipate during the peak and offset.
- Analysis enhancement
- Conceptual thinking
- Emotion enhancement
- Immersion enhancement
- Increased music appreciation
- Increased libido
- Memory suppression - Relative to other psychedelics, 2C-C does not produce this effect except at high doses.
- Ego death - Relative to other psychedelics, 2C-C does not produce this effect except at high doses.
- Novelty enhancement
- Personal bias suppression
- Thought acceleration
- Thought connectivity
- Time distortion
There are currently no anecdotal reports which describe the effects of this compound within our experience index. Additional experience reports can be found here:
Toxicity and harm potential
The toxicity and long-term health effects of recreational 2C-C use do not appear to have been studied in any scientific context and the exact toxic dose is unknown. This is because 2C-C is a research chemical with a limited history of human use.
Anecdotal reports from those who have tried this compound suggest that there are no negative health effects attributed to simply trying the substance by itself at low to moderate doses and using it very sparingly (although nothing can be completely guaranteed). Independent research should always be conducted to ensure that a combination of two or more substances is safe before consumption.
It is strongly recommended that one use harm reduction practices when using this substance.
Tolerance and addiction potential
Although no formal studies have been conducted, it is not unreasonable to assume that like psychedelics in general, 2C-C is not habit-forming and that the desire to use it can actually decrease with use.
Tolerance to the effects of 2C-C are built almost immediately after ingestion. After that, it takes about 3 days for the tolerance to be reduced to half and 7 days to be back at baseline (in the absence of further consumption). 2C-C presents cross-tolerance with all psychedelics, meaning that after the consumption of 2C-C all psychedelics will have a reduced effect.
Although many psychoactive substances are safe on their own, they can become dangerous and even life-threatening when combined with other substances. The list below contains some common potentially dangerous combinations, but may not include all of them. Certain combinations may be safe in low doses of each but still increase the potential risk of death. Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.
- Tramadol - Tramadol lowers the seizure threshold and psychedelics may act as triggers for seizures, particularly in those who are predisposed to them.
- Stimulants - Combining stimulants with psychedelics may induce states of uncontrollable anxiety, over-stimulation, thought loops, and increase the risk of psychosis.
- Lithium - Lithium is often used as treatment for bipolar disorder. It may possibly cause elevated risk of seizures and psychosis due to its glutaminergic and GABAergic effects.
- Australia: Australia has a blanket ban over all substituted phenethylamines including the entire 2C-X family.
- Brazil: Possession, production and sale is illegal as it is listed on Portaria SVS/MS nº 344.
- Canada: 2C-C would be considered Schedule III as it is a derivative of 2,5-dimethoxyphenethylamine.
- China: As of October 2015 2C-C is a controlled substance in China.
- Germany: On December 13, 2014 2C-C was added to the controlled substance act ("BtMG"), making it illegal to produce, sell or possess.
- Japan: 2C-C is controlled by the Pharmaceutical Affairs Law in Japan, making it illegal to possess or sell.
- Latvia: 2C-C is a Schedule I controlled substance.
- Sweden: 2C-C is classified as a health hazard as of March 1, 2005 in the regulation SFS 2005:26, making it illegal to sell or possess.
- Switzerland: Possession, production and sale is illegal.
- United Kingdom: 2C-C is a Class A drug in the United Kingdom as a result of the phenethylamine catch-all clause.
- United States: 2C-C is listed in Schedule I of section 202(c) of the Controlled Substances Act in the United States. This was signed into law as of July 2012 under the Food and Drug Administration Safety and Innovation Act.
- Alexander Shulgin - PIHKAL | http://www.erowid.org/library/books_online/pihkal/pihkal033.shtml
- Cheng, A. C., & Castagnoli Jr, N. (1984). Synthesis and physicochemical and neurotoxicity studies of 1-(4-substituted-2, 5-dihydroxyphenyl)-2-aminoethane analogs of 6-hydroxydopamine. Journal of medicinal chemistry, 27(4), 513-520. https://doi.org/10.1021/jm00370a014
- 2,5-Dimethoxy-4-chlorophenethylamine (Isomer Design / PiHKAL) | http://isomerdesign.com/PiHKAL/read.php?id=22
- Talaie, H., Panahandeh, R., Fayaznouri, M. R., Asadi, Z., & Abdollahi, M. (2009). Dose-independent occurrence of seizure with tramadol. Journal of medical toxicology, 5(2), 63-67. doi:10.1007/BF03161089
- Tripsit Factsheets - LSD | http://drugs.tripsit.me/lsd
- New Psychoactive Substances (National Drug and Alcohol Research Centre 2014) | https://comorbidity.edu.au/sites/default/files/cre/page/New%20Psychoactive%20Substances.pdf
- Controlled Drugs and Substances Act (S.C. 1996, c. 19) |http://laws-lois.justice.gc.ca/eng/acts/C-38.8/page-12.html#h-28
- "关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. 27 September 2015. Retrieved 1 October 2015.
- Achtundzwanzigste Verordnung zur Änderung betäubungsmittelrechtlicher Vorschriften (28. BtMÄndV)| http://www.buzer.de/gesetz/11392/a189949.htm
- Analytical Data of Designated Substances (Shitei-Yakubutsu) Controlled by the Pharmaceutical AŠairs Law in Japan, Part I: GC-MS and LC-MS | https://www.erowid.org/references/texts/show/7395docid7635
- Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem (2,5-Dimetoksifeniletānamīni) | http://likumi.lv/doc.php?id=121086
- Svensk författningssamling | http://www.notisum.se/rnp/sls/sfs/20050026.pdf
- United Kingdom. (1977). Misuse of Drugs Act 1971 (S.I. 1977/1243). London: The Stationery Office Limited. Retrieved July 5, 2017, from http://www.legislation.gov.uk/uksi/1977/1243/made
- S. 3187: Food and Drug Administration Safety and Innovation Act, Subtitle D-Synthetic Drugs | http://www.govtrack.us/congress/bills/112/s3187/text